The FDA has granted CanTx’s chemotherapy candidate drug, Cantrixil, Orphan Drug Designation for the treatment of ovarian cancer. CanTx is based in New Haven, CT and is a joint venture company between Yale University and Novogen (headquartered in Sydney, Australia). The active ingredient in Cantrixil is TRXE-002, a small molecule cytotoxic drug candidate. A cyclodextrin shell is used in Cantrixil to encapsulate TRXE-002. Cantrixil is designed specifically for injection into the peritoneal and pleural cavities to deliver a cytotoxic effect in a non-irritant and non-toxic fashion.